April 08, 2010 - New technologies enable accurate, non-invasive lung tumor treatment without additional intra-fraction radiation imaging -
Elekta has introduced an advanced solution for treating lung tumors that enables doctors to visually confirm the tumor’s position during the breathing cycle. This new technology treats the lesion with a continuous radiation beam, increasing therapy accuracy while using less imaging radiation during treatment delivery.
Lung tumors have been among the most challenging radiation therapy targets because the patient’s breathing causes tumors to move. New research has shown that the lung tumor shifts position from day to day during the course of treatment (baseline shift).1 Doctors often have had to use external skin surface markers or implanted markers to estimate lung tumor position during the breathing cycle and then apply the beam only during certain points in the patient’s respiration. These strategies require complex, time-consuming planning and delivery, and prolong treatment with an inefficient stop-start (i.e., gated) beam delivery.
“Elekta’s XVI Symmetry ™ and XVI Intuity™ completely change the approach when it comes to the treatment of lung tumors,”... Elekta's Press Release -
Blog Archive
-
▼
2010
(63)
-
▼
April
(18)
- BioMarin Pharmaceutical : Positive Results for Pha...
- deCODE genetics "deCODEing Smoking: New Genetic Fa...
- Biodesix : VeriStrat® Outcomes Data in Lung Cancer...
- Johnson & Johnson Pharmaceutical Research and Deve...
- GeNO LLC : Investigational New Drug Application f...
- Spectrum Pharmaceuticals : Belinostat Data Present...
- Ariad : Preclinical Data on Its Investigational AL...
- Synta Pharmaceuticals : Results at AACR Supporting...
- Graceway Pharmaceuticals : Maxair Autohaler Remain...
- Patient Enrollment Complete in Tragara Pharmaceuti...
- Invida Group : Actelion Extends Partnership with I...
- Phadia : point of care in vitro specific IgE aller...
- Elekta : Next Generation SBRT for Lung Cancer with...
- NeoPharm : Orphan Drug Application Filing for IL13...
- Merrimack Pharmaceuticals : Enrollment in a Phase ...
- Clinical Data : Results of Phase I Studies of Sted...
- Pearl Therapeutics : Positive Results from Phase 1...
- Vectura to receive $9.5m payment and up to $25m lo...
-
▼
April
(18)